CYP2C19 and depressive symptom measurement: Regarding the response to treatment in the studies reviewed, Świechowski et al. [39] found a statistically significant correlation between the CYP2C19*2 allele presence and clinical improvement after pharmacotherapy, as assessed by the Hamilton Depression Rating Scale (HDRS), as carriers of at least one *2 allele exhibited better responses to treatment.